Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Metis TechBio Co., Ltd.
劑泰科技(北京)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 7666)

VOLUNTARY ANNOUNCEMENT
ON-MARKET SHARE REPURCHASE UNDER GENERAL MANDATE

This announcement is made by Metis TechBio Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**" or "**Metis TechBio**") on a voluntary basis.

The board of directors (the "**Board**") of the Company hereby announces that the Company intends to repurchase the H shares of the Company (the "**H Shares**") on the open market from time to time for an aggregate amount of up to HK$300 million (the "**Share Repurchase**"), pursuant to the general mandate to repurchase H Shares (the "**Repurchase Mandate**") approved by the shareholders of the Company (the "**Shareholders**") at the annual general meeting of the Company held on April 22, 2026 (the "**AGM**").

The Share Repurchase will be funded by the Company's own funds or self-raised funds (other than the proceeds raised from its global offering) that may lawfully be used for share repurchases under applicable laws and regulations. The Share Repurchase period will commence from the date of this announcement and expire on the earliest of: (1) the conclusion of the next annual general meeting of the Company (unless a special resolution (whether with or without conditions) is passed at that meeting to unconditionally or conditionally renew the mandate, in which case the mandate shall not lapse at that time); or (2) the revocation or variation of the mandate granted under this resolution by a special resolution passed at any general meeting of the Company. The Company will conduct the Share Repurchase in compliance with its articles of association, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the Codes on Takeovers and Mergers and Share Buy-backs, the laws of the People's Republic of China and all other applicable laws and regulations governing the Company, and after obtaining the approval of the relevant regulatory authorities (if required). The Company will thereafter deal with such repurchased H Shares in such manner as the Board considers appropriate in accordance with applicable laws and regulations and the Company's articles of association.

The Board considers that the Share Repurchase under the current circumstances will demonstrate the Company's confidence in its own business prospects and outlook, and will ultimately benefit the Company and the Shareholders. The Board also considers that the Company's current financial resources will enable it to maintain a solid financial position while implementing the Share Repurchase.

As of the date of this announcement, the Company has not repurchased any H Shares under the Repurchase Mandate.

The Company will subsequently cancel and/or hold in treasury the repurchased H Shares, if any, as deemed appropriate by the Board. The proposed Share Repurchase shall not result in the number of the H Shares held by the public falling below the relevant minimum percentage prescribed by the Listing Rules.

Shareholders and potential investors should note that the implementation of the on-market Share Repurchase by the Company will be subject to market conditions and will be conducted at the absolute discretion of the Board and/or its authorized person(s). There is no assurance of the timing, quantity or price of any repurchases or whether the Company will repurchase any shares at all. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Metis TechBio Co., Ltd.
Tsai-Ta Lai
Chairman of the Board, executive Director and chief executive officer

Hong Kong, November 20, 2026

As of the date of this announcement, the Board comprises Dr. Tsai-Ta Lai, Dr. Hongming Chen and Dr. Wenshou Wang as executive Directors; Mr. Hantao Huang and Ms. Yuan Gong as non-executive Directors; and Mr. Frank Yee Chon Lyn, Dr. Jin Li and Dr. Peter Edward Lobie as independent non-executive Directors.